Compare ROMA & VANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ROMA | VANI |
|---|---|---|
| Founded | 2018 | 1998 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 542.0M | 119.0M |
| IPO Year | 2022 | 2014 |
| Metric | ROMA | VANI |
|---|---|---|
| Price | $8.98 | $1.25 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.50 |
| AVG Volume (30 Days) | 3.0K | ★ 231.2K |
| Earning Date | 12-23-2025 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.16 | $0.92 |
| 52 Week High | $11.77 | $1.92 |
| Indicator | ROMA | VANI |
|---|---|---|
| Relative Strength Index (RSI) | 50.90 | 40.80 |
| Support Level | $8.01 | $1.26 |
| Resistance Level | $9.75 | $1.55 |
| Average True Range (ATR) | 0.35 | 0.08 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 74.59 | 3.74 |
Roma Green Finance Ltd is a professional specialist in the provision of environmental, social and governance (ESG), sustainability and climate change related advisory services through its operating subsidiaries in Hong Kong and Singapore. Its services include Sustainability Program Development, ESG Reporting, Corporate Governance and Risk Management, Climate Change Strategies and Solutions, Environmental Audit, ESG Rating Support and Shareholder Communication, and Education and Training. It operates in one reporting business segment in Hong Kong and Singapore, of which the majority of revenue is derived from Hong Kong.
Vivani Medical Inc is a clinical stage biopharmaceutical company which develops miniature, ultra long-acting subdermal drug implant candidates utilizing its proprietary NanoPortal technology, which is designed to enable reversible, ultra long-acting, near constant-rate delivery of a broad range of medicines to treat chronic diseases. Vivani uses this platform technology to develop, and potentially commercialize, drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address causes of poor clinical outcomes in the treatment of chronic diseases, including medication non-adherence, drug tolerability and administration challenges faced by certain patients. It operates in two segments the Biopharm Division and Neurostimulation Division.